Revenue - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended		24 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Mar. 31, 2020
Disaggregation Of Revenue [Line Items]
Contract with customer liability, revenue recognized	$ 6,300,000	$ 1,800,000	$ 7,700,000	$ 3,400,000
Deferred revenue	32,004,000	$ 31,232,000	32,004,000	$ 31,232,000	$ 34,954,000	$ 26,321,000	$ 34,954,000
Research, Collaboration and License Agreement | Eli Lilly
Disaggregation Of Revenue [Line Items]
Contract with customer liability, revenue recognized	3,800,000		4,300,000
Upfront payment received			0.6		$ 1,700,000	26,700,000	$ 28,400,000
Deferred revenue						$ 21,900,000
Research, Collaboration and License Agreement | Maximum | Eli Lilly
Disaggregation Of Revenue [Line Items]
Milestone payment threshold amount								$ 29,000,000.0
Low to mid-teens royalty threshold sales amount								125,000,000.0
Research, Collaboration and License Agreement | Minimum [Member] | Eli Lilly
Disaggregation Of Revenue [Line Items]
Mid-teens to mid-twenties royalty threshold sales amount								$ 125,000,000.0
Various Other Agreements
Disaggregation Of Revenue [Line Items]
Deferred revenue	$ 15,200,000		$ 15,200,000